# Sanuj Ravindran

> Sanuj Ravindran, M.D., is the CEO of Simcha Therapeutics, a New Haven clinical-stage immunobiology company turning a once-overlooked immune molecule, interleukin-18, into a cancer weapon. A board-certified physician who spent a decade as a venture capitalist before becoming a serial biotech company-builder, Ravindran took the helm in 2022 to push ST-067, a decoy-resistant IL-18 designed to slip past the body's own off-switch and reawaken the immune system inside tumors. He has run drug programs across oncology and rare disease, structured more than $2 billion in deals, and bets his career on therapies that promise more than incremental gains.

- **Role:** Chief Executive Officer & Director at Simcha Therapeutics
- **Organizations:** Simcha Therapeutics, BridgeBio Pharma, PellePharm, Phoenix Tissue Repair, aTyr Pharma, The Medicines Company, Burrill & Company, Radius Ventures, Asian Healthcare Fund
- **Nationality:** American
- **Education:** B.A., Northwestern University, M.D., Jefferson Medical College, Thomas Jefferson University, Residency, Internal Medicine, Thomas Jefferson University Hospital, MBA (Finance, Entrepreneurship, Biotechnology Management), Kellogg School of Management, Northwestern University
- **Known for:** Leads Simcha Therapeutics, advancing ST-067, a first-in-class decoy-resistant IL-18 immunotherapy, through Phase 1/2 trials in solid tumors, Helped position Simcha's Series B and expanded research collaboration with Yale School of Medicine, As SVP of Corporate Development at The Medicines Company, led transactions exceeding $2 billion in value

## Career timeline

- **2002** — Summer Associate at Merrill Lynch, early step into finance
- **2000s** — Spent roughly a decade as a venture capitalist with Burrill & Company, Radius Ventures, and the Asian Healthcare Fund
- **2010s** — Senior Vice President of Corporate Development at The Medicines Company, leading transactions valued at more than $2 billion
- **2016** — Appointed Chief Business Officer at aTyr Pharma
- **2017** — Joined BridgeBio Pharma as CEO-in-Residence; named President and CEO of PellePharm and Executive Chair of Phoenix Tissue Repair
- **2022** — Appointed Chief Executive Officer and Director of Simcha Therapeutics (August)

## Achievements

- Leads Simcha Therapeutics, advancing ST-067, a first-in-class decoy-resistant IL-18 immunotherapy, through Phase 1/2 trials in solid tumors
- Helped position Simcha's Series B and expanded research collaboration with Yale School of Medicine
- As SVP of Corporate Development at The Medicines Company, led transactions exceeding $2 billion in value
- Built and led multiple clinical-stage biotechs across oncology and rare disease at BridgeBio (PellePharm, Phoenix Tissue Repair)
- Board-certified physician in Internal Medicine who pivoted to building therapeutics

## Latest updates

- **2022-08** — Appointed CEO and Director of Simcha Therapeutics.
- **2022-01** — Simcha closed a $40M Series B led by SR One and dosed the first patient in the Phase 1/2 study of ST-067.

## Links

- Website: https://simchatx.com
- LinkedIn: https://www.linkedin.com/in/sanujravindran/

---

Profile page: https://yespress.io/sanuj-ravindran
Published by YesPress — https://yespress.io
Last updated: 2026-06-20